טוען...
Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease
Parkinson’s disease (PD) is characterized by severe locomotor deficits and is commonly treated with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (l-DOPA), but its prolonged use causes dyskinesias referred to as l-DOPA–induced dyskinesias (LIDs). Recent studies in animal models of PD have...
שמור ב:
| הוצא לאור ב: | Proc Natl Acad Sci U S A |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
National Academy of Sciences
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4434696/ https://ncbi.nlm.nih.gov/pubmed/25918399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1502740112 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|